TGF-β/Smad Signaling


The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
BA2805 DecursinSummary: Decursin ((+)-Decursin) is a potent antitumor agent. -
BA2859 BJE6-106Summary: BJE6-106 (B106) is a potent and selective inhibitor. -
C8575 Bisindolylmaleimide III -
N2891 Trimethylamine oxide dihydrateSummary: ROS/NLRP3 activator; TGF-β/Smad2 signaling pathway activator -
C3371 PsychosineSummary: A natural substrate of GALC, induces apoptosis and inhibits PKC activity. -
C4359 ProstratinSummary: PKC activator -
C5222 IngenolSummary: A compound that activates PKC and is used for anti-tumor research. -
C5393 1-Oleoyl-2-acetyl-sn-glycerolSummary: A cell-permeable analog of DAG

